Paper Details

  1. Home
  2. Paper Details

Systematic Review on Parkinson's Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson's Symptoms.

Author: HongPhoon Kok, LeeyTan Choo, LingTan Chi, SemilanSamantha Lia Anak, SivanandyPalanisamy, Wey HanSean Ang, XiangTan Chi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Parkinson's disease (PD) affects millions worldwide, causing tremors, stiffness, and slow movements. While there are existing medications, they have limitations. This review looked at three newer medications approved in the US between 2016 and 2019: safinamide, istradefylline, and pimavanserin. Safinamide, when used in addition to levodopa, a common PD medication, showed greater effectiveness and safety in reducing movement symptoms compared to istradefylline. Pimavanserin was also found to be helpful in treating psychosis, which can occur in some people with Parkinson's. The review emphasizes the need for a combination of conventional and non-medication approaches to improve the well-being of people with PD.
Paper Details　
Original Abstract of the Article :
Parkinson's Disease (PD) is a disease that involves neurodegeneration and is characterised by the motor symptoms which include muscle rigidity, tremor, and bradykinesia. Other non-motor symptoms include pain, depression, anxiety, and psychosis. This disease affects up to ten million people worldwide...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744877/

データ提供：米国国立医学図書館（NLM）

Navigating the Labyrinth of Parkinson's Disease

The study of Parkinson's Disease (PD) is a complex and challenging journey, like traversing a vast and winding desert landscape. Researchers are constantly searching for new and improved treatments to alleviate the debilitating symptoms of this neurodegenerative disease. This study explores the effectiveness and safety of three recently approved drugs: safinamide, istradefylline, and pimavanserin, focusing on their potential to control PD symptoms.

A New Compass for Parkinson's Treatment

The study provides a comprehensive review of recent advancements in PD medication, highlighting the potential of these new drugs to improve treatment outcomes. The findings suggest that safinamide, when used as an adjunct therapy with levodopa, may be more effective and safer than istradefylline in controlling motor symptoms. Furthermore, pimavanserin demonstrates favorable effects in managing Parkinson's Disease Psychosis (PDP). Think of these new drugs as a new compass, guiding us towards more effective and safe treatment options for PD.

Finding Oasis in the Desert of Parkinson's

The study underscores the importance of exploring new and innovative treatments for PD. The development of these new drugs offers hope for patients seeking better symptom control and improved quality of life. It's like discovering a refreshing oasis in the midst of a challenging desert, providing much-needed relief and hope for those living with PD.

Dr.Camel's Conclusion

This study offers valuable insights into the latest advancements in PD medication, particularly the promising potential of safinamide as a more effective and safer adjunct therapy with levodopa. It highlights the importance of ongoing research and development of new treatment strategies to combat this debilitating disease.

Date :
  1. Date Completed 2022-01-24
  2. Date Revised 2023-11-05
Further Info :

Pubmed ID

35010624

DOI: Digital Object Identifier

PMC8744877

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.